Trials / Completed
CompletedNCT04667156
Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects
A Single-centre, Single Dose, Randomized, Open-label, Three Period, Six Sequence, Cross Controlled Study to Assess the Relative Bioavailability of the New and Traditional Formulations on SHR6390 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate relative bioavailability during the new and traditional formulations of SHR6390 in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR6390 | SHR6390 new formulation 1(T1) , SHR6390 new formulation 2 (T2) and SHR6390 traditional formulatin were given in a single dose over three cycles |
Timeline
- Start date
- 2020-12-13
- Primary completion
- 2021-01-29
- Completion
- 2021-01-29
- First posted
- 2020-12-14
- Last updated
- 2021-10-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04667156. Inclusion in this directory is not an endorsement.